NASDAQ:GRCE Grace Therapeutics (GRCE) Stock Price, News & Analysis $1.77 -0.04 (-2.21%) As of 02:27 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Grace Therapeutics Stock (NASDAQ:GRCE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Grace Therapeutics alerts:Sign Up Key Stats Today's Range$1.75▼$1.8350-Day Range$1.78▼$2.2952-Week Range$1.67▼$5.18Volume19,591 shsAverage Volume342,790 shsMarket Capitalization$37.23 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for rare and orphan diseases. Its drug candidates are designed to address conditions with limited treatment options, including neurological disorders. The company’s pipeline includes GTX-104, a formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, as well as GTX-102 for ataxia-telangiectasia and GTX-101 for postherpetic neuralgia. These programs use alternative delivery approaches intended to address limitations associated with existing treatments. Grace Therapeutics was formerly known as Acasti Pharma and adopted its current name as it focused on the development programs associated with Grace Therapeutics. The company’s candidates remain investigational and are not approved medicines.AI Generated. May Contain Errors. Read More Grace Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreGRCE MarketRank™: 1.97638944157 of 5 starsGrace Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 667th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingGrace Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialGrace Therapeutics has a consensus price target of $6.00, representing about 238.0% upside from its current price of $1.78.Amount of Analyst CoverageGrace Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Grace Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Grace Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Grace Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGrace Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.89% of the float of Grace Therapeutics has been sold short.Short Interest Ratio / Days to CoverGrace Therapeutics has a short interest ratio ("days to cover") of 12.33, which indicates bearish sentiment.Change versus previous monthShort interest in Grace Therapeutics has recently decreased by 0.95%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGrace Therapeutics does not currently pay a dividend.Dividend GrowthGrace Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.81 News SentimentGrace Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Grace Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for GRCE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Grace Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Grace Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.84% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions6.08% of the stock of Grace Therapeutics is held by institutions.Read more about Grace Therapeutics' insider trading history. Receive GRCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Grace Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRCE Stock News HeadlinesGrace Therapeutics (NASDAQ:GRCE) Stock Rating Raised to "Sell" at Wall Street ZenNovember 15 at 10:11 AM | americanbankingnews.comGrace Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026November 13 at 6:40 PM | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 16 at 1:00 AM | Base Camp Trading (Ad)Grace: Fiscal Q2 earnings snapshotNovember 12, 2026 | msn.comGrace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business UpdateNovember 12, 2026 | markets.businessinsider.comGrace Therapeutics (NASDAQ:GRCE) Stock Rating Cut to Strong Sell at Wall Street ZenNovember 7, 2026 | americanbankingnews.comGrace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026November 5, 2026 | globenewswire.comGrace Therapeutics (GRCE) Expected to Release Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comSee More Headlines GRCE Stock Analysis - Frequently Asked Questions How have GRCE shares performed this year? Grace Therapeutics' stock was trading at $3.46 at the beginning of the year. Since then, GRCE shares have decreased by 48.7% and is now trading at $1.7750. How were Grace Therapeutics' earnings last quarter? Grace Therapeutics, Inc. (NASDAQ:GRCE) issued its earnings results on Thursday, November, 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. How do I buy shares of Grace Therapeutics? Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2026Today11/16/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GRCE's financial health is in the Red zone, according to TradeSmith. GRCE has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GRCE Previous SymbolNASDAQ:GRCE CIK1444192 Webwww.gracetx.com Phone(609) 322-1602Fax45-0687-2272Employees5Year FoundedN/APrice Target and Rating Average Price Target for Grace Therapeutics$6.00 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+239.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.00% Return on Assets-35.53% Debt Debt-to-Equity RatioN/A Current Ratio13.61 Quick Ratio13.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.99 per share Price / Book0.44Miscellaneous Outstanding Shares21,036,000Free Float18,756,000Market Cap$37.23 million OptionableOptionable Beta0.43 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:GRCE) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.